Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DK210 (CD19)
- Development stage
- Preclinical
- Lead developer
- DEKA Biosciences
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
DK210 (CD19) is an investigational engineered cytokine fusion protein developed by DEKA Biosciences using its proprietary Diakine™ platform. The therapeutic candidate is designed to treat hematological cancers by targeting the B-lymphocyte antigen CD19, a well-validated marker for B-cell malignancies. The DK210 scaffold typically consists of a combination of interleukin-2 (IL-2) and interleukin-10 (IL-10) cytokines, which are engineered and fused to a targeting moiety (such as an antibody fragment) directed against CD19. This targeted approach is intended to concentrate the immunomodulatory effects of the cytokines within the tumor microenvironment, thereby enhancing the anti-tumor immune response while minimizing the systemic toxicities often associated with high-dose cytokine therapy.
- Other names
- CD19-targeted DiakineCD-19-targeted DiakineCD 19-targeted DiakineDK210-CD19DK-210-CD19DK 210-CD19
02
Targets
IL10RA (Interleukin-10 Receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on DK210 (CD19).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DK210 (CD19).